Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Common Equity of -$1.4 million for Q4 2025, down 93.13% on a YoY basis from -$20.8 million in Q4 2024, and down 13.37% sequentially from -$1.3 million in Q3 2025.
Raphael Pharmaceutical (RAPH) Common Equity (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Common Equity data on file, last reported at -$1.4 million in Q4 2025.
- For the quarter ending Q4 2025, Common Equity fell 93.13% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2025 stood at -$1.4 million (down 93.13% YoY), and the FY2025 full-year result was -$1.4 million, down 93.13% from the prior year.
- Common Equity slipped to -$1.4 million in Q4 2025, from -$1.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $191000.0 in Q2 2021 to a low of -$1.4 million in Q4 2025.
- A 5-year average of -$305350.0 and a median of -$89000.0 in 2023 frame the typical range for Common Equity.
- Across the five-year window, Common Equity surged 397.67% in 2021 and slumped 1044.44% in 2024, its largest moves.
- Tracing RAPH's Common Equity over 5 years: stood at $128000.0 in 2021, then decreased by 17.19% to $106000.0 in 2022, then gained by 0.94% to $107000.0 in 2023, then slumped by 793.46% to -$742000.0 in 2024, then plunged by 93.13% to -$1.4 million in 2025.
- Business Quant data shows RAPH's Common Equity at -$1.4 million in Q4 2025, -$1.3 million in Q3 2025, and -$1.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.43 Mn |
| Sep 30, 2025 | -1.26 Mn |
| Jun 30, 2025 | -1.05 Mn |
| Mar 31, 2025 | -734,000.00 |
| Dec 31, 2024 | -742,000.00 |
| Sep 30, 2024 | -616,000.00 |
| Jun 30, 2024 | -290,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | -75,000.00 |
| Jun 30, 2023 | -61,000.00 |
| Mar 31, 2023 | -9,000.00 |
| Dec 31, 2022 | 106,000.00 |
| Sep 30, 2022 | -62,000.00 |
| Jun 30, 2022 | 118,000.00 |
| Mar 31, 2022 | 103,000.00 |
| Dec 31, 2021 | 128,000.00 |
| Sep 30, 2021 | -125,000.00 |
| Jun 30, 2021 | 191,000.00 |
| Mar 31, 2021 | -298,000.00 |